Kezar Life Sciences Past Earnings Performance
Past criteria checks 0/6
Kezar Life Sciences's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 103.7% per year.
Key information
-25.8%
Earnings growth rate
11.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 103.7% |
| Return on equity | -54.3% |
| Net Margin | -1,455.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08
FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Revenue & Expenses BreakdownBeta
How Kezar Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -102 | 27 | 9 |
| 30 Sep 23 | 7 | -88 | 26 | 54 |
| 30 Jun 23 | 0 | -83 | 22 | 68 |
| 31 Mar 23 | 0 | -74 | 21 | 58 |
| 31 Dec 22 | 0 | -68 | 20 | 7 |
| 30 Sep 22 | 0 | -64 | 19 | 15 |
| 30 Jun 22 | 0 | -61 | 18 | 43 |
| 31 Mar 22 | 0 | -58 | 17 | 41 |
| 31 Dec 21 | 0 | -55 | 16 | 3 |
| 30 Sep 21 | 0 | -51 | 14 | 37 |
| 30 Jun 21 | 0 | -48 | 14 | 35 |
| 31 Mar 21 | 0 | -45 | 13 | 33 |
| 31 Dec 20 | 0 | -42 | 12 | 31 |
| 30 Sep 20 | 0 | -40 | 12 | 30 |
| 30 Jun 20 | 0 | -38 | 11 | 29 |
| 31 Mar 20 | 0 | -37 | 11 | 29 |
| 31 Dec 19 | 0 | -35 | 10 | 27 |
| 30 Sep 19 | 0 | -31 | 9 | 25 |
| 30 Jun 19 | 0 | -28 | 8 | 22 |
| 31 Mar 19 | 0 | -26 | 7 | 20 |
| 31 Dec 18 | 0 | -23 | 7 | 18 |
| 30 Sep 18 | 0 | -20 | 6 | 15 |
| 30 Jun 18 | 0 | -16 | 5 | 12 |
| 31 Mar 18 | 0 | -11 | 3 | 8 |
| 31 Dec 17 | 0 | -9 | 2 | 6 |
Quality Earnings: KZR is currently unprofitable.
Growing Profit Margin: KZR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KZR is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare KZR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KZR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: KZR has a negative Return on Equity (-54.31%), as it is currently unprofitable.